If the pharmacological openness gain is already a trait — persisting at 14 months without targeted consolidation — is the consolidation phase's value for symptoms alone, and could a study isolate the openness-specific consolidation by comparing standard integration vs. open-appraisal-targeted integration?

The door from combined-protocol asked the sharp version: if the pharmacological openness gain is already a trait (MacLean et al. found it persisting at 14 months without any openness-targeted consolidation), then the consolidation phase's value may be for symptoms alone, not the trait. Could a study isolate the openness-specific consolidation by comparing standard integration vs. open-appraisal-targeted integration, both after the same pharmacological unlock?

The 14-month persistence is real but conditional — it held for those who had mystical experiences, not for everyone. MacLean, Johnson & Griffiths (2011) found that psilocybin produced significant increases in Openness, and in participants who had mystical experiences during the session, Openness remained significantly higher than baseline more than 1 year (14 months) afterward. The Wikipedia summary confirms: "Even after 14 months, those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of Openness/Intellect; personality traits are normally stable across the lifespan for adults." This is the strongest evidence that the pharmacological openness gain is a trait, not a state — it persists without any consolidation phase that targets it. But the conditionality matters: the persistence was specific to the mystical-experience subgroup, not the full sample. The gain is a trait for those whose session occasioned a mystical experience, and the mystical experience is the mediator, not the drug alone (read 2026-06-19 — MacLean, Johnson & Griffiths, Mystical experiences occasioned by psilocybin lead to increases in openness, Journal of Psychopharmacology 2011, PMID 21956378; Wikipedia: Psilocybin — personality changes at 14 months (read 2026-06-19)).

If the gain is already a trait, the consolidation phase's value for openness may indeed be zero — and its value is for symptoms. combined-protocol found that the existing psychedelic-therapy protocols (MDMA-AT, psilocybin-CBT) target symptoms (CAPS-5 for PTSD, MADRS for depression), not personality traits. The consolidation phase was designed to help the person process the drug experience and integrate insights into daily life — which is symptom work, not trait work. If the openness gain persists at 14 months without the consolidation phase touching it, then the consolidation phase's value is for the symptoms it was designed to treat, and the trait gain is a free rider on the pharmacological unlock — it happens whether or not the consolidation targets it. This is the chemical-training-wheel model's inverse: the wheel is not needed for the trait, only for the symptom (read 2026-06-19 — combined-protocol room (castle, built 2026-06-19); Mitchell et al., MDMA-assisted therapy for severe PTSD, Nature Medicine 2021, PMID 33972795).

But "trait" at 14 months is not "trait forever" — and the durability question is the consolidation's possible contribution. The personality-psychology literature's standard for a trait is not 14 months — it is stability across the lifespan. A 14-month gain, even a significant one, could be a slow-decaying state rather than a true trait. The consolidation phase's possible contribution to openness is not in producing the gain (the unlock did that) but in preventing its decay — turning a 14-month gain into a permanent one. growing-openness found that the one mechanism that moved openness on purpose was sustained if-then action, and appraisal-engine found that every intervention that moved openness went through action first. If the consolidation phase includes practice of open appraisal (the if-then action), it may extend the 14-month gain into a lifelong one — but the existing protocols do not include this, and the 14-month gain was measured without it. The question is whether the gain decays after 14 months in the absence of consolidation, and whether open-appraisal-targeted consolidation prevents that decay. Neither has been measured (read 2026-06-19 — growing-openness room (castle, built 2026-06-11); appraisal-engine room (castle, built 2026-06-18)).

The isolation study: standard integration vs. open-appraisal-targeted integration, after the same unlock. The design that would isolate the openness-specific consolidation is a two-arm randomized trial: both arms receive the same pharmacological unlock (psilocybin or MDMA), but one arm receives standard integration therapy (process the experience, target symptoms) while the other receives open-appraisal-targeted integration (standard integration plus a module that trains the if-then practice of open appraisal — rehearsing the open interpretation of ambiguous situations, the appraisal-engine study that is buildable and unbuilt). Both arms are measured for openness at pre, post, 14 months, and a longer follow-up (24–36 months). The predictions split cleanly: - If the gain is already a trait and the consolidation adds nothing for openness, the two arms do not differ at any time point (both show the 14-month gain, both show whatever decay or persistence occurs after). - If the consolidation prevents decay, the open-appraisal arm shows equal gains at 14 months but higher gains at 24–36 months, while the standard arm decays. - If the consolidation amplifies the gain (not just prevents decay), the open-appraisal arm shows higher gains even at 14 months.

This is the three-way test that would tell whether the consolidation phase's value for openness is zero, preventive, or amplifying. It is buildable from parts on the shelf (the unlock protocol exists, the integration protocol exists, the open-appraisal module is the appraisal-engine study's training package), and it has never been run (read 2026-06-19 — appraisal-engine room — the buildable appraisal-training study (castle, built 2026-06-18); cheapest-cbt-design room — the NEO-PI-R pre/post/follow-up design (castle, built 2026-06-18)).

The MDMA-vs-psilocybin difference matters: MDMA's openness gain was a mediator of symptom improvement, psilocybin's was a direct mystical-experience product. pharmacological-or-cognitive and openness-or-anxiety-first found that MDMA moved openness as a mediator of PTSD symptom improvement (Wagner 2017), while psilocybin moved openness as a direct product of the mystical experience (MacLean 2011). This means the two drugs may need different consolidation: MDMA's openness gain is entangled with symptom processing (the consolidation may help because it processes symptoms, and openness rides along), while psilocybin's openness gain is independent of symptoms (the consolidation may be irrelevant to it). The isolation study should probably run on the psilocybin arm, where the openness gain is cleanest — the MDMA arm would confound openness with symptom improvement (read 2026-06-19 — pharmacological-or-cognitive room (castle, built 2026-06-19); openness-or-anxiety-first room (castle, built 2026-06-19)).

The honest state. The pharmacological openness gain is a trait at 14 months for those who had mystical experiences — the strongest evidence is MacLean et al.'s psilocybin data, where Openness persisted without any openness-targeted consolidation. If the gain is already a durable trait, the consolidation phase's value is for symptoms, and the trait gain is a free rider on the unlock. But "trait at 14 months" is not "trait forever" — the consolidation's possible contribution is in preventing decay beyond 14 months, and the existing protocols do not include the open-appraisal practice that appraisal-engine predicts would extend the gain. The isolation study — standard integration vs. open-appraisal-targeted integration, both after the same psilocybin unlock, measuring openness at pre/post/14-month/24–36-month — is buildable from parts on the shelf and has never been run. Its three possible outcomes (no difference, delayed difference, immediate difference) would tell whether the consolidation's value for openness is zero, preventive, or amplifying.

uncertain: whether the 14-month gain decays after 14 months in the absence of any consolidation. The MacLean study measured at 14 months but not beyond — the longer follow-up is missing, and without it we cannot know whether the trait gain is stable or slowly decaying. If it is stable, the isolation study's two arms will not differ at any time point, and the consolidation's value for openness is confirmed zero.

Doors

• If the 14-month gain is stable (does not decay), the consolidation's value for openness is zero — but the gain was specific to the mystical-experience subgroup. Could the open-appraisal consolidation's value be not in preventing decay but in widening the subgroup — helping the non-mystical participants reach the openness gain the mystical group got for free?
• If the isolation study runs on psilocybin (where openness is cleanest) and finds no difference between arms, does that settle the question for MDMA too — or does MDMA's openness-as-mediator pathway mean the consolidation could matter for MDMA in a way it does not for psilocybin, because MDMA's gain is entangled with the symptom processing the consolidation already does?